Diagnostic test using chimeric antibodies
CA 2007336 C · Owner: Boehringer Mannheim Gmbh · Inventors: Kaluza, Brigitte; Lenz, Helmut
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Chimeric monoclonal antibodies or fragments thereof are used according to the present invention in diagnostic tests for the quantitative immunological determination of substances in the blood or serum of patients. For the diagnostic detection of substances in serum or blood of patients by binding of two monoclonal antibodies R1 and R2 directed against the substance, of which the first antibody R1 is capable of binding to a solid phase or is already bound and the second antibody R2 carries a label, binding of the antibody R1 to the solid phase if desired, separation of the complex formed of R1 substance and R2 which is bound to the solid phase and detection via the labelling of the antibody …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 8, 1990 and granted January 2, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 8, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 8, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.